Itacitinib

Generic Name: Itacitinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₃F_₄N_₉O

CAS Number: 1334298-90-6

Unique Ingredient Identifier: 19J3781LPM

Background: Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

First Posted Date: 2020-10-19

Last Posted Date: 2023-10-03

Lead Sponsor: Fondazione per la Medicina Personalizzata

Target Recruit Count: 400

Registration Number: NCT04591431

Locations: 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹
Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹
I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy

and more 34 locations

Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD

Phase 2

Terminated

Conditions: Chronic Graft-versus-host-disease

Interventions: Drug: Itacitinib
Device: Extracorporeal Photopheresis (ECP)

First Posted Date: 2020-06-24

Last Posted Date: 2024-01-22

Lead Sponsor: University of Utah

Target Recruit Count: 3

Registration Number: NCT04446182

Locations: 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant

Phase 1

Active, not recruiting

Conditions: Bronchiolitis Obliterans

Interventions: Drug: Itacitinib
Drug: Itacitinib Adipate

First Posted Date: 2020-01-27

Last Posted Date: 2024-10-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT04239989

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

Phase 1

Terminated

Conditions: GVHD,Acute

Interventions: Drug: Itacitinib
Drug: Prednisone
Drug: Methylprednisolone

First Posted Date: 2020-01-07

Last Posted Date: 2020-10-29

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 1

Registration Number: NCT04220632

Locations: 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China

A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)

Phase 2

Terminated

Conditions: Chronic Graft-versus-host-disease

Interventions: Drug: Itacitinib

First Posted Date: 2019-12-16

Last Posted Date: 2024-11-06

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 15

Registration Number: NCT04200365

Locations: 🇺🇸
Texas Oncology - Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Texas Transplant Institute, San Antonio, Texas, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 2 locations

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Phase 2

Withdrawn

Conditions: Allogeneic Stem Cell Transplant Recipient
Hematopoietic and Lymphoid Cell Neoplasm
Hematologic and Lymphocytic Disorder

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Fludarabine
Drug: Itacitinib
Drug: Methotrexate
Drug: Tacrolimus

First Posted Date: 2019-10-16

Last Posted Date: 2020-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04127721

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

Phase 1

Terminated

Conditions: Steroid Refractory GVHD
Graft Vs Host Disease

Interventions: Drug: Itacitinib
Drug: Tocilizumab

First Posted Date: 2019-08-28

Last Posted Date: 2024-06-04

Lead Sponsor: Columbia University

Target Recruit Count: 1

Registration Number: NCT04070781

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York, United States

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Phase 2

Completed

Conditions: Cytokine Release Syndrome

Interventions: Drug: Itacitinib
Drug: Immune effector cell therapy
Drug: Placebo
Biological: Yescarta

First Posted Date: 2019-08-28

Last Posted Date: 2024-03-26

Lead Sponsor: Incyte Corporation

Target Recruit Count: 112

Registration Number: NCT04071366

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 7 locations

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

Phase 1

Recruiting

Conditions: MDS/MPN

Interventions: Drug: ASTX727
Drug: Itacitinib

First Posted Date: 2019-08-19

Last Posted Date: 2023-06-26

Lead Sponsor: Michael Savona

Target Recruit Count: 105

Registration Number: NCT04061421

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Phase 1

Completed

Conditions: Recurrent T-Cell Prolymphocytic Leukemia
T-Cell Prolymphocytic Leukemia

Interventions: Biological: Alemtuzumab
Drug: Itacitinib

First Posted Date: 2019-06-18

Last Posted Date: 2024-10-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT03989466

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy